Hal Lewis, MD
Dermatology · Carbondale, ILNPI 1124554209
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $105,925 of the $137,854 with a category attached, or 76.8%. 26 manufacturers reported payments, led by Amgen at 54.2% of the total. 2025 is the largest year on record at $52,906, more than ten times the $475 reported in 2019. Among dermatology clinicians in IL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 587 payments — averaging $234.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$75K
- AbbVie$50K
- E.r. Squibb & Sons, L.L.C.$8K
- Novartis$932
- Johnson & Johnson$845
- Lilly USA, LLC$524
- plus $2K from 20 others
What the payments were for
- Consulting fees$9,3507%
- Speaking & faculty fees$105,92577%
- Travel & lodging$12,3379%
- Food & beverage$9,9037%
- Education$3390%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 99 | $74,742 |
| AbbVie(2 entities) | 173 | $49,995 |
| E.r. Squibb & Sons, L.L.C. | 85 | $8,467 |
| Novartis | 49 | $932 |
| Johnson & Johnson | 23 | $845 |
| Lilly USA, LLC | 48 | $524 |
| Regeneron Healthcare Solutions, Inc. | 15 | $446 |
| Incyte Corporation | 14 | $233 |
| Sun Pharmaceutical Industries Inc. | 13 | $218 |
| UCB, Inc. | 10 | $210 |
| Galderma Laboratories, L.p. | 4 | $195 |
| Sanofi | 9 | $181 |
| Pfizer | 9 | $167 |
| Organon | 12 | $116 |
| Strata Skin Sciences, Inc. | 1 | $113 |
| Dermavant Sciences, Inc. | 6 | $103 |
| Almirall LLC | 6 | $99 |
| Sanofi-aventis U.S. LLC | 1 | $69 |
| LEO Pharma Inc. | 3 | $64 |
| Polynovo North America LLC | 1 | $25 |
| Revance Therapeutics, Inc. | 1 | $23 |
| Sientra, Inc. | 1 | $20 |
| Journey Medical Corporation | 1 | $17 |
| KCI USA, Inc. | 1 | $17 |
| Botanix SB Inc | 1 | $16 |
| Arcutis Biotherapeutics, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$137,854 in reported general payments places this provider in the 95th percentile of 606 dermatology providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Skyrizi PenRisankizumab-Rzaa | 35 | $712,131 |
| Taltz AutoinjectorIxekizumab | 35 | $231,380 |
| Dupixent PenDupilumab | 30 | $108,695 |
| SotyktuDeucravacitinib | 15 | $96,129 |
| Humira(Cf) PenAdalimumab | 11 | $74,927 |
| OtezlaApremilast | 12 | $64,951 |
| Fluorouracil | 297 | $21,912 |
| Clobetasol Propionate | 419 | $19,917 |
| Triamcinolone Acetonide | 285 | $4,039 |
| Tacrolimus | 30 | $3,639 |
| Fluocinonide | 63 | $3,086 |
| Metronidazole | 60 | $2,835 |
| Ketoconazole | 85 | $2,439 |
| Clindamycin Phosphate | 63 | $2,216 |
| Doxycycline Hyclate | 126 | $2,072 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| E.r. Squibb & Sons, L.L.C.Sotyktu | $8,467 | $96,12915 claims |
| AmgenOtezla | $74,742 | $64,95112 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 606 dermatology providers in Illinois.
Other dermatology in Carbondale
- Ahmad AminNaperville$4.1M
- Raj ChovatiyaChicago$3.6M
- George LewittNorthbrook$3M
- Peter LioChicago$2.4M
- Elizabeth KiracofeChicago$1.6M
- Lana SchmidtEffingham$1.3M
- Melissa AbramsVernon Hills$600K
- Carolyn JacobChicago$566K
- Walter LiszewskiChicago$414K
- Emily RubensteinLincolnshire$359K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.